Sep 18, 2023 Cellectar Biosciences Receives European Medicines Agency Priority Medicines (PRIME) Designation for Iopofosine for Waldenstrom’s Macroglobulinemia Learn More
Sep 11, 2023 Cellectar Biosciences Announces Closing of up to Approximately $103 Million Private Placement Financing Learn More
Sep 5, 2023 Cellectar Biosciences Announces up to Approximately $103 Million Private Placement Financing Learn More
Aug 14, 2023 Cellectar Reports Financial Results for Second Quarter 2023 and Provides a Corporate Update Learn More